Revenue segments as reported by the company.

Product revenue

Service and other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Goodwill Impairment

Restructuring costs

Intangible assets and other long-lived assets impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bionano Genomics

Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bionano Genomics reports robust Q1 performance and strategic growth plans

Bionano Genomics demonstrated strong revenue growth and operational progress in Q1 2024.
While facing short-term revenue challenges, the company's strategic initiatives and product advancements position it for long-term success.
Efforts to reduce expenses and expand the customer base underscore Bionano's commitment to sustainable growth.

Bionano Genomics reports Q2 revenue decline, focuses on growth strategies

Bionano Genomics faced revenue decline in Q2 2024, attributed to discontinued services and challenges in China.
Despite operational streamlining efforts, the company aims to drive growth through product advancements and partnerships.
Lowered revenue guidance underscores the need for strategic adjustments to navigate market challenges and optimize performance.

Bionano Genomics reports Q3 revenue decline but shows cost efficiency

Bionano Genomics showcased operational improvements with cost reductions and growth in key metrics despite a revenue decline.
The company's focus on expense reduction, revenue growth, and profitability sets a strategic direction for future success.
Challenges persist in revenue generation and cost management, but opportunities in technology adoption and market expansion are evident.
Overall, Bionano Genomics aims to balance financial stability with growth initiatives to drive long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that company management will present at the 43rd Annual Cowen Healthcare Conference. Erik Holmlin, Ph.D., Bionano's president and chief executive officer, is scheduled to present a corporate overview on Monday, March 6th, 2023 at 1:30 pm ET.

Bionano to Present at the 43rd Annual Cowen Healthcare Conference

SAN DIEGO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced that its Chinese original equipment manufacturing (OEM) partner, Beijing Genome Precision Technology (BGPT), a comprehensive molecular diagnostics company, has obtained reagent class I registrations from China's National Medical Products Administration (NMPA) for Bionano's DNA extraction kit and labeling products.

Bionano Announces China NMPA Approval for DNA Extraction and Labeling Products for IVD Use in Hematologic Malignancies

SAN DIEGO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced details of topics covered at the company's pre-conference workshop during the Advances in Genome Biology and Technology (AGBT) 2023 General Meeting, which took place February 6-9, 2023 in Hollywood, Florida. Bionano leaders Alka Chaubey, PhD, FACMG, chief medical officer, Alex Hastie, PhD, vice president of clinical and scientific affairs, Marc Meyers, head of product management, and Klint Rose, PhD, fellow, ITP technology development, delivered presentations on optical genome mapping (OGM) and its potential to replace traditional cytogenetic methods for structural variant (SV) detection, as well as an overview of the company's new product advancements. Damla Senol Cali, PhD, staff software engineer, hardware acceleration at Bionano and George Vacek, PhD, global head of genomics alliances at NVIDIA previewed the companies' collaborative development, a next-generation compute solution for the analysis of OGM data from high throughput systems. Sheila Purim, PhD, MBA, senior director of segment marketing, announced the Bionano Innovator Research Grant, which will award five winners with OGM technology designed to fuel research in a number of areas, including hematologic malignancies, cell therapy, reproductive health and precision medicine. Adam Smith, PhD, FCCMG, FACMG, erCLG from University Health Network, University of Toronto, presented on use of the VIA software in his clinical research, and Alexander Hoischen, PhD, from Radboud Genomics Technology Center presented on use of OGM for SV detection in rare disease research. Bionano and NVIDIA presenters, along with Drs. Smith and Hoischen, also participated in live Q&A sessions with the audience.

Bionano Shares Overview of AGBT Pre-Conference Workshop Program Along with Details of Company's Innovative Research Grant Opportunity

Here is how Bionano Genomics, Inc. (BNGO) and Amarin (AMRN) have performed compared to their sector so far this year.

Is Bionano Genomics (BNGO) Stock Outpacing Its Medical Peers This Year?

Pacific Biosciences of California

Sangamo Therapeutics

These cutting-edge biotech companies quickly fell out of favor with investors this week.

Why Bionano Genomics, Pacific Biosciences of California, and Sangamo Therapeutics Stocks Crumbled This Week

Here is how Bionano Genomics, Inc. (BNGO) and Aziyo Biologics, Inc. (AZYO) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Bionano Genomics (BNGO) This Year?

SAN DIEGO, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO today announced the launch of multiple new products and advancements for its optical genome mapping (OGM) workflow that offer enhanced robustness in sample preparation, decreased turnaround time for DNA labeling and imaging, and improvements in throughput and quality metrics. The new versions of Bionano's sample prep kits, chips and instrument software address customer feedback and can improve the performance in routine higher volume genome analysis applications.

Bionano Announces Launch of Next-Generation Versions of its Reagent Kits and Chip Consumable, Along with Updates to its Instrument Control and Bionano Access Software for the Optical Genome Mapping Workflow

Ocugen, Inc.

Opendoor

Select analysts expect these small-caps stocks to catapult higher in the new year.

3 Under-the-Radar Stocks With 590% to 772% Upside in 2023, According to Wall Street

SAN DIEGO, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its Symposium 2023 lineup of 30 oral presentations delivered from 27 different customers worldwide featuring the utility of optical genome mapping (OGM) across a wide range of applications for genetic disease and cancer research and for cell bioprocessing. The symposium will take place virtually from January 23 to 26, 2023. During these four days, customers will showcase their latest research findings using OGM. Each day will feature oral customer presentations, a live panel with Q&A and a wide range of scientific posters within the virtual exhibition hall.

Bionano Genomics Announces the Final Speaker Lineup for Symposium 2023 with 30 OGM Presentations and Live Panel Discussions Across a Wide Range of Genetic Disease and Cancer Research Applications

Amazon

Inmode Ltd

Plug Power

Rivian Automotive

Shoals Technologies Group

Super Micro Computer

With the Nasdaq Composite having risen a robust 6% in the first two weeks of the New Year, it appears that the exchange, in line with my previous predictions, is well on its way to entering a bull market. Further, recent developments, including strong holiday-season retail sales growth and a month-over-month drop in December's Consumer Price Index, indicate that the Street's fears about the macro environment last year were tremendously overdone.

7 Must-Buy Nasdaq Stocks to Kick Off the First Quarter

IRB-approved, multi-site, ongoing study evaluated 200 samples representing 123 unique prenatal cases across 9 sites for interim measures of key endpoints:

Bionano Announces Publication of Interim Readout from Clinical Trial Run by Consortium Analyzing Optical Genome Mapping as Potential Standard of Care for Prenatal Testing

SAN DIEGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a collaboration with NVIDIA to develop an acceleration platform for use in Bionano's optical genome mapping (OGM) workflow. This collaboration is expected to significantly improve data processing speed while reducing time and cost associated with secondary analysis of OGM data. The computation platform is designed to enable a small laboratory and information technology footprint, which would allow for rapid decentralized deployment.

Bionano to Accelerate Data Processing Solution for Optical Genome Mapping Workflow with NVIDIA

This could be a great day for medical science as well as for investors of Bionano Genomics (NASDAQ: BNGO ) stock. The biotech company just announced the publication of results concerning a proposed method to help detect breast cancer.

Bionano Genomics (BNGO) Stock Pops on Promising Publication

Aprea Therapeutics

Eton Pharmaceuticals Inc

Fresh Tracks Therapeutics Inc

4 Biotech Penny Stocks To Watch, January 2023 The post Best Penny Stocks To Buy? 4 To Watch In January 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy? 4 To Watch In January 2023

SAN DIEGO, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced that it will host its first-ever Strategy Day on Thursday, February 2nd, 2023, at the Nasdaq MarketSite in New York City, starting at 1:30 PM ET. The event will include presentations from members of the company's leadership team and panel discussions featuring key opinion leaders in basic and clinical research areas including cancer, genetic disorders and cell bioprocessing. Bionano panel members will also participate in a Q&A discussion with the audience.

Bionano Genomics to Host Strategy Day on February 2, 2023 in New York City

- Preliminary Q4 revenue expected to be between $8.1 and $8.4 million; 29% to 33% increase over Q4 2021- Reached installed base of 240 systems as of YE 2022; 46% increase over YE 2021- Achieved or exceeded all stated goals and milestones for the full year 2022

Bionano Genomics Reports Preliminary Fourth Quarter and Full-Year 2022 Results

MGM Resorts

NXP Semiconductors

Tesla

XPeng

A bull-bear battle is starting to materialize in the stock market, and I believe that the struggle will intensify in early 2023. Bears believe that we're heading for a steep recession and a horrible macro environment for stocks, and many of them are looking for unprofitable growth equities to short.

The Top 7 Stocks to Watch in 2023

Investors have high expectations for Bionano Genomics, but they might not pan out.

This Innovative Growth Stock Could Double or More in 2023

GlaxoSmithKline

iCAD

Madrigal Pharmaceuticals

Schrodinger 

Verona Pharma

vTv Therapeutics

Choosing the best drug stocks to buy can be dicey because drug stocks have disadvantages and advantages. On the negative side, you often have to wait many years for promising drugs to prove themselves in clinical trials.

7 Drug Stocks That Will Soar in 2023

Bionano Genomics, Inc. is an engaging company operating in the genome mapping space. The company generated $7.2m of revenues from 217 installed bases in Q322.

Bionano Genomics: Still Waiting For Genome Mapping Market To Reveal Itself

SAN DIEGO, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a multi-institutional peer-reviewed study initiated by the Cancer Genomics Consortium evaluating the performance of optical genome mapping (OGM) for detection of cytogenetic abnormalities in acute myeloid leukemia (AML) samples. OGM identified structural variants (SVs) and copy number variants (CNVs) with 100% concordance to traditional cytogenetic methods, added important pathogenic findings in 13% of findings, and uncovered additional genomic events in 12% of samples that may change risk stratification and alter recommended clinical care, including access to clinical trials.

Multi-Center Research Study Illustrates How OGM Can Potentially Result in More Patients Qualifying for Treatments in Leukemia

SAN DIEGO, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation in the American Society of Hematology (ASH) Annual Meeting and Exposition 2022 with a broad range of content covering optical genome mapping's (OGM) utility for research areas including myeloid cancer, hematological malignancy, leukemia and blood disorders.

Bionano Genomics Announces American Society of Hematology (ASH) Annual Meeting Presentations Featuring OGM Utility Across Blood Cancer Research Applications

Geron

Muscle Maker

The Very Good Food Co

Penny stocks to watch this week. The post 4 Penny Stocks To Watch With Big News In December 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Watch With Big News In December 2022

Novavax

Select Wall Street analysts believe these fast-growing companies could skyrocket next year.

3 Supercharged Growth Stocks With 393% to 1,153% Upside in 2023, According to Wall Street

Bionano Genomics, Inc. (BNGO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

News for Bionano Genomics Stock (BNGO)